Business Description
Adagene Inc
ISIN : US0053291078
Share Class Description:
ADAG: ADRDescription
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.93 | |||||
| Equity-to-Asset | 0.61 | |||||
| Debt-to-Equity | 0.32 | |||||
| Debt-to-EBITDA | -1.38 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -1.26 | |||||
| Beneish M-Score | -1.98 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 189.9 | |||||
| 3-Year EBITDA Growth Rate | 29.7 | |||||
| 3-Year EPS without NRI Growth Rate | 52.9 | |||||
| 3-Year FCF Growth Rate | 2.3 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 44.33 | |||||
| 9-Day RSI | 44.63 | |||||
| 14-Day RSI | 45.18 | |||||
| 6-1 Month Momentum % | 75 | |||||
| 12-1 Month Momentum % | 78.72 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.61 | |||||
| Quick Ratio | 3.61 | |||||
| Cash Ratio | 3.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.5 | |||||
| Shareholder Yield % | -1.1 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -130.96 | |||||
| Net Margin % | -104.61 | |||||
| FCF Margin % | -157.58 | |||||
| ROE % | -24.04 | |||||
| ROA % | -14.09 | |||||
| ROIC % | -134.11 | |||||
| ROC (Joel Greenblatt) % | -629.92 | |||||
| ROCE % | -17.43 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.86 | |||||
| PB Ratio | 1.72 | |||||
| Price-to-Tangible-Book | 1.72 | |||||
| EV-to-EBIT | -1.82 | |||||
| EV-to-EBITDA | -1.82 | |||||
| EV-to-Revenue | 1.62 | |||||
| EV-to-FCF | -1.03 | |||||
| Price-to-Net-Current-Asset-Value | 1.77 | |||||
| Price-to-Net-Cash | 1.87 | |||||
| Earnings Yield (Greenblatt) % | -54.95 | |||||
| FCF Yield % | -23.5 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers